Your browser doesn't support javascript.
loading
Inflammatory biomarkers in Alzheimer's disease plasma.
Morgan, Angharad R; Touchard, Samuel; Leckey, Claire; O'Hagan, Caroline; Nevado-Holgado, Alejo J; Barkhof, Frederik; Bertram, Lars; Blin, Olivier; Bos, Isabelle; Dobricic, Valerija; Engelborghs, Sebastiaan; Frisoni, Giovanni; Frölich, Lutz; Gabel, Silvey; Johannsen, Peter; Kettunen, Petronella; Kloszewska, Iwona; Legido-Quigley, Cristina; Lleó, Alberto; Martinez-Lage, Pablo; Mecocci, Patrizia; Meersmans, Karen; Molinuevo, José Luis; Peyratout, Gwendoline; Popp, Julius; Richardson, Jill; Sala, Isabel; Scheltens, Philip; Streffer, Johannes; Soininen, Hikka; Tainta-Cuezva, Mikel; Teunissen, Charlotte; Tsolaki, Magda; Vandenberghe, Rik; Visser, Pieter Jelle; Vos, Stephanie; Wahlund, Lars-Olof; Wallin, Anders; Westwood, Sarah; Zetterberg, Henrik; Lovestone, Simon; Morgan, B Paul.
Affiliation
  • Morgan AR; Systems Immunity Research Institute and UK Dementia Research Institute Cardiff, School of Medicine, Cardiff University, Cardiff, UK.
  • Touchard S; Systems Immunity Research Institute and UK Dementia Research Institute Cardiff, School of Medicine, Cardiff University, Cardiff, UK.
  • Leckey C; Systems Immunity Research Institute and UK Dementia Research Institute Cardiff, School of Medicine, Cardiff University, Cardiff, UK.
  • O'Hagan C; Systems Immunity Research Institute and UK Dementia Research Institute Cardiff, School of Medicine, Cardiff University, Cardiff, UK.
  • Nevado-Holgado AJ; Department of Psychiatry, University of Oxford, Oxford, UK.
  • Barkhof F; Department of Radiology and Nuclear Medicine, VU University Medical, Amsterdam, the Netherlands; UCL Institutes of Neurology and Healthcare Engineering, University College London, London, UK.
  • Bertram L; Max Planck Institute for Molecular Genetics, Berlin, Germany.
  • Blin O; Aix-Marseille University, APHM, Institute Neurosci System, Pharmacology, Marseille, France.
  • Bos I; Alzheimer Centrum Limburg, Maastricht University, Maastricht, the Netherlands.
  • Dobricic V; Lübeck Interdisciplinary Platform for Genome Analytics, University of Lübeck, Lübeck, Germany.
  • Engelborghs S; Department of Neurology, Hospital Network Antwerp (ZNA), Antwerp, Belgium; Reference Center for Biological Markers of Dementia, Institute Born-Bunge, Antwerp, Belgium.
  • Frisoni G; University of Geneva, Geneva, Switzerland; IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
  • Frölich L; Department of Geriatric Psychiatry, Zentralinstitut für Seelische Gesundheit, University of Heidelberg, Mannheim, Germany.
  • Gabel S; Department of Neurosciences, Laboratory for Cognitive Neurology, KU Leuven, Leuven, Belgium.
  • Johannsen P; Division of Clinical Geriatrics, Department of Neurobiology, Caring Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
  • Kettunen P; University of Gothenburg, Institute of Neuroscience and Physiology, Gothenburg, Sweden.
  • Kloszewska I; Department of Old Age Psychiatry & Psychotic Disorders, Medical University of Lodz, Lodz, Poland.
  • Legido-Quigley C; UCL Institutes of Neurology and Healthcare Engineering, University College London, London, UK; School of Public Health, Imperial College London, London, UK.
  • Lleó A; Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Martinez-Lage P; CITA-Alzheimer Foundation, San Sebastian, Spain.
  • Mecocci P; Department of Medicine, Institute of Gerontology and Geriatrics, University of Perugia, Perugia, Italy.
  • Meersmans K; Department of Neurosciences, Laboratory for Cognitive Neurology, KU Leuven, Leuven, Belgium.
  • Molinuevo JL; Barcelona Beta Brain Research Center, Unversitat Pompeu Fabra, Barcelona, Spain.
  • Peyratout G; Department of Psychiatry, Old Age Psychiatry, Lausanne University Hospital, Lausanne, Switzerland.
  • Popp J; Hopitaux Universitaires Geneve and Universite de Geneve, Geneva, Switzerland.
  • Richardson J; Neurosciences Therapeutic Area, GlaxoSmithKline R&D, Stevenage, UK.
  • Sala I; Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Scheltens P; Alzheimer Center, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, the Netherlands.
  • Streffer J; Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
  • Soininen H; Institute of Clinical Medicine, Neurology, University of Eastern Finland, Kuopio, Finland.
  • Tainta-Cuezva M; Center for Research and Advanced Therapies. CITA-Alzheimer Foundation, San Sebastian, Spain.
  • Teunissen C; University Hospital Leuven, Leuven, Belgium.
  • Tsolaki M; 1st Department of Neurology, AHEPA University Hospital, Makedonia, Thessaloniki, Greece.
  • Vandenberghe R; Department of Clinical Chemistry, Neurochemistry lab, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
  • Visser PJ; Department of Psychiatry & Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.
  • Vos S; Alzheimer Centrum Limburg, Maastricht University, Maastricht, the Netherlands.
  • Wahlund LO; NVS-Department, Section of Clinical Geriatrics, Karolinska Institutet, Huddinge, Sweden.
  • Wallin A; Section for Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg Sahlgrenska Academy, Gothenburg, Sweden.
  • Westwood S; Department of Psychiatry, University of Oxford, Oxford, UK.
  • Zetterberg H; Clinical Neurochemistry Lab, Institute of Neuroscience and Physiology, Sahlgrenska University Hospital, Mölndal, Sweden; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, University of Gothenburg, Mölndal, Sweden; Department of Molecular Neuroscience, UCL Institu
  • Lovestone S; Department of Psychiatry, University of Oxford, Oxford, UK.
  • Morgan BP; Systems Immunity Research Institute and UK Dementia Research Institute Cardiff, School of Medicine, Cardiff University, Cardiff, UK. Electronic address: morganbp@cardiff.ac.uk.
Alzheimers Dement ; 15(6): 776-787, 2019 06.
Article in En | MEDLINE | ID: mdl-31047856
ABSTRACT

INTRODUCTION:

Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a "Holy Grail" of AD research and intensively sought; however, there are no well-established plasma markers.

METHODS:

A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed.

RESULTS:

Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1) that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC 0.79), and three (sCR1, MCP-1, eotaxin-1) that optimally differentiated AD and MCI (AUC 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH) plus age predicted MCI progression to AD (AUC 0.71).

DISCUSSION:

Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Biomarkers / Alzheimer Disease / Cognitive Dysfunction / Inflammation Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Humans Language: En Journal: Alzheimers Dement Year: 2019 Type: Article Affiliation country: United kingdom

Full text: 1 Database: MEDLINE Main subject: Biomarkers / Alzheimer Disease / Cognitive Dysfunction / Inflammation Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Humans Language: En Journal: Alzheimers Dement Year: 2019 Type: Article Affiliation country: United kingdom